Frazier Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Frazier Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.9K	Buy	29 +21	+263%	+$9.79K	0.01%	374
2025 Q4	$3.63K	Hold	8	–	–	﹤0.01%	508
2025 Q3	$3.13K	Hold	8	–	–	﹤0.01%	497
2025 Q2	$3.56K	Hold	8	–	–	﹤0.01%	495
2025 Q1	$3.88K	Hold	8	–	–	﹤0.01%	466
2024 Q4	$3.19K	Sell	8 -5	-38%	-$2.32K	﹤0.01%	486
2024 Q3	$6.05K	Sell	13 -10	-43%	-$4.8K	﹤0.01%	488
2024 Q2	$10.8K	Sell	23 -4	-15%	-$1.74K	0.01%	421
2024 Q1	$11.3K	Buy	27 +14	+108%	+$5.92K	0.01%	386
2023 Q4	$5.29K	Buy	+13	New	+$4.8K	﹤0.01%	479

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Frazier Financial Advisors's VRTX Position: Q1 2026 in Review

Frazier Financial Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 263% in Q1 2026, buying an estimated $9.79K and bringing the position to 29 shares worth $12.9K. The position accounts for 0.01% of the portfolio, ranked #374.

Frazier Financial Advisors first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Frazier Financial Advisors held 29 shares of Vertex Pharmaceuticals worth $12.9K as of Q1 2026.
Frazier Financial Advisors bought 21 Vertex Pharmaceuticals shares in Q1 2026, an estimated $9.79K.
Vertex Pharmaceuticals made up 0.01% of Frazier Financial Advisors's portfolio in Q1 2026, its #374 holding.
Frazier Financial Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Frazier Financial Advisors's 13F filing for Q1 2026, filed 5 May 2026.